Alteplase is the first recombinant tissue plasminogen activator (rtPA or tPA) that was approved by the United States Food and Drug Administration (U.S. FDA) for the treatment of thromboembolic diseases [1], including AIS, following the National Institute of Neurological Disorders and Stroke (NINDS) trial [2]. Here, PLAT is linked to stroke disorder.